Date: 2011-02-22
Type of information: Commercialisation agreement
Compound: immunohematology instruments, assays, semi-automated pre-transfusion diagnostic products
Company: Grifols (Spain) Novartis (Switzerland)
Therapeutic area:
Type agreement: commercialisation distribution
Action mechanism:
Disease:
Details: Grifols, has entered into a long-term cooperative agreement with the diagnostics business of Novartis for the commercialization of select Grifols' diagnostic products in the US. Under the terms of the agreement, Novartis will market and distribute Grifols' immunohematology instruments, assays and other products following US regulatory approvals. The agreement also covers semi-automated pre-transfusion diagnostic products made by Grifols subsidiaries as well as Progenika blood group antigen genotyping products currently distributed by Grifols. The agreement comes on the heels of the completion of a new Medion Grifols production facility in Switzerland that makes reagents for the rapid identification of blood groups. It also follows a threefold production capacity increase for Grifols' immunohematology gel cards in 2009 at its Barcelona facility. All of Grifols' diagnostic production facilities in Spain are ISO 13485 certified and meet leading industry standards for quality.
Financial terms:
Latest news:
